EpiCast Report: Age-Related Macular Degeneration – Epidemiology Forecast to 2026

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the total prevalent cases (including both diagnosed and undiagnosed) as well as the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, late wet AMD, and large drusen in the 7MM.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.

the total prevalent cases of AMD in the 7MM will increase from 71,787,702 cases in 2016 to 82,997,296 cases in 2026, at an Annual Growth Rate (AGR) of 1.56% over the forecast period. Throughout the forecast period, Japan will have the highest number of total prevalent cases of AMD, followed by Italy. The total prevalent cases of AMD in Japan and Italy combined will make up approximately 39.28% of the total prevalent cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the total prevalent cases of AMD in the 7MM to the changing population demographics in the respective markets.

Scope

The Age-related Macular Degeneration (AMD) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report also includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets. GlobalData epidemiologists also provided the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older). Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed incident cases of large drusen (≥125 µm) segmented by sex and age (ages 50 years and older) in these markets.

The AMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The AMD EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global AMD market.

Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AMD therapeutics in each of the markets covered.

Understand magnitude of AMD population by type.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Age-Related Macular Degeneration: Executive Summary

2.1 Related Reports

2.2 ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Age-Related Macular Degeneration: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

3.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

3.5 Epidemiological Forecast for AMD (2016–2026)

3.5.1 Total Prevalent Cases of AMD

3.5.2 Age-Specific Total Prevalent Cases of AMD

3.5.3 Sex-Specific Total Prevalent Cases of AMD

3.5.4 Total Prevalent Cases of Early AMD

3.5.5 Total Prevalent Cases of Late AMD

3.5.6 Total Prevalent Cases of Late Dry AMD

3.5.7 Total Prevalent Cases of Late Wet AMD

3.5.8 Total Prevalent Cases of Large Drusen

3.5.9 Diagnosed Incident Cases of AMD

3.5.10 Age-Specific Diagnosed Incident Cases of AMD

3.5.11 Sex-Specific Diagnosed Incident Cases of AMD

3.5.12 Diagnosed Incident Cases of Early AMD

3.5.13 Diagnosed Incident Cases of Late AMD

3.5.14 Diagnosed Incident Cases of Late Dry AMD

3.5.15 Diagnosed Incident Cases of Late Wet AMD

3.5.16 Diagnosed Incident Cases of Large Drusen

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbid Conditions Associated with AMD

Table 2: Classification of AMD

Table 3: 7MM, Total Prevalent Cases of AMD, Both Sexes, ...

Table 1: Risk Factors and Comorbid Conditions Associated with AMD

Table 2: Classification of AMD

Table 3: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 4: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 5: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 6: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 7: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, N, Ages ≥50 Years, Selected Years 2016–2026

Table 8: 7MM, Total Prevalent Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 9: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 10: 7MM, Diagnosed Incident Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 11: 7MM, Diagnosed Incident Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 12: 7MM, Diagnosed Incident Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 13: 7MM, Diagnosed Incident Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

Table 14: 7MM, Diagnosed Incident Cases of Large Drusen, Both Sexes, Ages ≥50 Years, N, Selected Years 2016–2026

List of Figures

Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026

Figure 2: 7MM, Diagnosed Incident Cases of AMD, ...

Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026

Figure 2: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2016 and 2026

Figure 3: 7MM, Age-Standardized Total Prevalence of AMD (%), Men and Women, Ages ≥50 Years, 2016

Figure 4: 7MM, Sources Used, Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

Figure 6: 7MM, Age-Specific Total Prevalent Cases of AMD, Both Sexes, N, 2016

Figure 7: 7MM, Sex-Specific Total Prevalent Cases of AMD, Ages ≥50 Years, N, 2016

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of AMD, Both Sexes, N, 2016

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of AMD, Ages ≥50 Years, N, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports